The Microenvironment of the Pathogenesis of Cardiac Hypertrophy
Pathological cardiac hypertrophy is a key risk factor for the development of heart failure and predisposes individuals to cardiac arrhythmia and sudden death. While physiological cardiac hypertrophy is adaptive, hypertrophy resulting from conditions comprising hypertension, aortic stenosis, or genet...
Main Authors: | Farhad Bazgir, Julia Nau, Saeideh Nakhaei-Rad, Ehsan Amin, Matthew J. Wolf, Jeffry J. Saucerman, Kristina Lorenz, Mohammad Reza Ahmadian |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/13/1780 |
Similar Items
-
Changes in glutamic oxaloacetic transaminase 2 during rat physiological and pathological cardiomyocyte hypertrophy
by: Xin Liu, et al.
Published: (2023-12-01) -
Novel Therapeutic Effects of Pterosin B on Ang II-Induced Cardiomyocyte Hypertrophy
by: Chang Youn Lee, et al.
Published: (2020-11-01) -
Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy
by: Ai-Lan Chen, et al.
Published: (2012-12-01) -
Whole-exome sequencing and an iPSC-derived cardiomyocyte model provides a powerful platform for gene discovery in left ventricular hypertrophy
by: Degui eZhi, et al.
Published: (2012-05-01) -
TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression
by: Bin-Bin Zhang, et al.
Published: (2024-09-01)